| Literature DB >> 23728494 |
Stefanie Marzian1, Phillip J Stansfeld, Markus Rapedius, Susanne Rinné, Ehsan Nematian-Ardestani, Jennifer L Abbruzzese, Klaus Steinmeyer, Mark S P Sansom, Michael C Sanguinetti, Thomas Baukrowitz, Niels Decher.
Abstract
Most known small-molecule inhibitors of voltage-gated ion channels have poor subtype specificity because they interact with a highly conserved binding site in the central cavity. Using alanine-scanning mutagenesis, electrophysiological recordings and molecular modeling, we have identified a new drug-binding site in Kv1.x channels. We report that Psora-4 can discriminate between related Kv channel subtypes because, in addition to binding the central pore cavity, it binds a second, less conserved site located in side pockets formed by the backsides of S5 and S6, the S4-S5 linker, part of the voltage sensor and the pore helix. Simultaneous drug occupation of both binding sites results in an extremely stable nonconducting state that confers high affinity, cooperativity, use-dependence and selectivity to Psora-4 inhibition of Kv1.x channels. This new mechanism of inhibition represents a molecular basis for the development of a new class of allosteric and selective voltage-gated channel inhibitors.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23728494 PMCID: PMC4539245 DOI: 10.1038/nchembio.1271
Source DB: PubMed Journal: Nat Chem Biol ISSN: 1552-4450 Impact factor: 16.174